This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session will conclude with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.
Supported through an independent educational grant from EQRx International, Inc.
Lung Cancer Patients and Members of the Interprofessional Lung Cancer Care Team, including Thoracic Medical Oncologists, Community Medical Oncologists, Other Physicians, Nurse Practitioners, Registered Nurses, and Pharmacists.
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit JA0007101-0000-22-009-H01-P
This activity is designated for 1.00 contact hour.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Helena Yu, MD–has disclosed that she is an advisor or consultant to AstraZeneca, Black Diamond, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, and Janssen. Her institution receives research support from AstraZeneca, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Erasca, Janssen, Novartis, and Pfizer.
Jill Feldman, MA–has disclosed that she is an advisor or consultant to Daiichi Sankyo, EQRx, and Janssen and receives speaking honoraria from AstraZeneca, Blueprint Medicines, and Takeda.
Lisa Shotyk, RN, MSN, APN-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO–has disclosed that she receives grants from Amgen, AstraZeneca, Bayer, EMD Serono, Guardant Health, Novartis, Pfizer, Roche, and. She receives research support from Bristol-Myers Squibb, Guardant Health, Inivata, Lilly, and Merck Sharp & Dohme. Dr. Leighl was an advisor/consultant for Beigene, GlaxoSmithKline, and Puma Biotechnology. She also receives other financial or material support from Amgen, Bristol-Myers Squibb, Genzyme, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, and Takeda.
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Joan B. Fowler, PharmD, BCPP–has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Rebecca Weaver, CHCP–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 859-260-1717 • email@example.com